These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 11772314)

  • 21. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis.
    Nolan CR; Qunibi WY
    Kidney Int Suppl; 2005 Jun; (95):S13-20. PubMed ID: 15882308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
    Almirall J; Lopez T; Vallve M; Ruiz A; Llibre J; Betriu A
    Nephron Clin Pract; 2004; 97(1):c17-22. PubMed ID: 15153763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia.
    O'Donovan R; Baldwin D; Hammer M; Moniz C; Parsons V
    Lancet; 1986 Apr; 1(8486):880-2. PubMed ID: 2870354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and cost-efficiency of phosphate binders in hemodialysis.
    Fröschl B; Brunner-Ziegler S; Hiebinger C; Wimmer A; Zsifkovits J
    GMS Health Technol Assess; 2009 Jun; 5():Doc08. PubMed ID: 21289895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphate binders for control of phosphate retention in chronic renal failure.
    Loghman-Adham M
    Pediatr Nephrol; 1999 Oct; 13(8):701-8. PubMed ID: 10502131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
    Savica V; Calò LA; Monardo P; Santoro D; Bellinghieri G
    Nephrol Dial Transplant; 2006 Aug; 21(8):2065-8. PubMed ID: 16766546
    [No Abstract]   [Full Text] [Related]  

  • 27. Control of hyperphosphatemia among patients with ESRD.
    Coladonato JA
    J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S107-14. PubMed ID: 16251245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyperphosphatemia in end-stage renal disease.
    Indridason OS; Quarles LD
    Adv Ren Replace Ther; 2002 Jul; 9(3):184-92. PubMed ID: 12203200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel dosage forms and regimens for sevelamer-based phosphate binders.
    Duggal A; Hanus M; Zhorov E; Dagher R; Plone MA; Goldberg J; Burke SK
    J Ren Nutr; 2006 Jul; 16(3):248-52. PubMed ID: 16825030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacological and clinical trial data on a novel phosphate-binding polymer (sevelamer hydrochloride), a medicine for hyperphosphatemia in hemodialysis patients].
    Nagano N; Fukushima N
    Nihon Yakurigaku Zasshi; 2003 Nov; 122(5):443-53. PubMed ID: 14569164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
    Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders.
    Brewster UC; Ciampi MA; Abu-Alfa AK; Reilly RF
    Nephrology (Carlton); 2006 Apr; 11(2):142-6. PubMed ID: 16669977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The phosphate binder equivalent dose.
    Daugirdas JT; Finn WF; Emmett M; Chertow GM;
    Semin Dial; 2011; 24(1):41-9. PubMed ID: 21338393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
    Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients.
    Locatelli F; Dimkovic N; Spasovski G
    Expert Opin Pharmacother; 2014 Jul; 15(10):1475-88. PubMed ID: 24914480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperphosphatemia and phosphate binders.
    Schucker JJ; Ward KE
    Am J Health Syst Pharm; 2005 Nov; 62(22):2355-61. PubMed ID: 16278327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.